Summary of Study ST002467

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench,, where it has been assigned Project ID PR001593. The data can be accessed directly via it's Project DOI: 10.21228/M8SH9M This work is supported by NIH grant, U2C- DK119886.


This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST002467
Study TitleNano-hijacked myeloid cells potentiate antitumor immunity and radiotherapy for glioblastoma
Study TypeIR versus IR + LNP
Study SummaryAbstract: Radiation therapy is a key component of the standard of care for glioblastoma (GBM). Although this treatment is known to trigger pro-inflammatory immune responses, it also results in several immune resistance mechanisms such as the upregulation of CD47 by tumors leading to avoidance of phagocytosis and the overexpression of PD-L1 in tumor-associated myeloid cells (TAMCs). Leveraging these RT-elicited processes, we generated a bispecific-lipid nanoparticle (B-LNP) that engaged TAMCs to glioma cells via anti-CD47/PD-L1 dual-ligation. We show that B-LNP blocked these two vital immune checkpoint molecules and promoted the phagocytic activity of TAMCs. In order to boost subsequent T cell recruitment and antitumor activity after tumor engulfment, the B-LNP was encapsulated with diABZI, a non-nucleotidyl agonist for stimulator of interferon genes (STING). In vivo treatment with the diABZI-loaded B-LNP induced a transcriptomic and metabolic switch in TAMCs, transforming them into potent antitumor effector cells, which induced T cell infiltration and activation of in the brain tumors. In preclinical murine glioma models, B-LNP therapy significantly potentiated the antitumor effects of radiotherapy, promoted brain tumor regression, and induced immunological memory against gliomas. The nano37 therapy was efficacious through both intra-tumoral and systemic delivery routes. In summary, our study shows a unique nanotechnology-based approach that hijacks multiple immune checkpoints to boost potent and long-lasting antitumor immunity against GBM.
Northwestern University, Feinberg School of Medicine
DepartmentNeurological Surgery
LaboratoryJason Miska
Last NameMiska
First NameJason
Address676 N St. Clair
Submit Date2023-02-06
Num Groups2
Total Subjects6
Raw Data AvailableYes
Raw Data File Type(s)raw(Thermo)
Analysis Type DetailLC-MS
Release Date2023-02-21
Release Version1
Jason Miska Jason Miska application/zip

Select appropriate tab below to view additional metadata details:

Combined analysis:

Analysis ID AN004023
Analysis type MS
Chromatography type HILIC
Chromatography system Q Exactive™ Plus Hybrid Quadrupole-Orbitrap™ Mass Spectrometer
Column Water's Xbridge amide (100 x 3mm, 3.5 um)
MS instrument type Orbitrap
MS instrument name Thermo Q Exactive Plus Orbitrap
Units Normalized peak area